Fiche publication
Date publication
juillet 2022
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Storme S, Debieuvre D, Souquet PJ, Toffart AC, Couraud S
Lien Pubmed
Résumé
Concerns about the proper schedule for discontinuing immunotherapy have been raised by many clinicians, as well as the minimal check-up required to assess residual disease before stopping immunotherapy. In fact, there currently exist no recommendations concerning immunotherapy prescription and optimal assessment in the event of persistent oncological response in cases of metastatic non-small cell lung cancer (NSCLC).
Mots clés
Carcinome pulmonaire non à petites cellules, Duration of therapy, Durée du traitement, Enquêtes et questionnaires, Immune checkpoint inhibitors, Immunotherapy, Immunothérapie, Inhibiteurs des points de contrôle immunitaire, Non-small-cell lung carcinoma, Surveys and questionnaires
Référence
Rev Mal Respir. 2022 07 28;:
